Navigation Links
Amira Pharmaceuticals Achieves Milestones in FLAP Inhibitor Program With GlaxoSmithKline
Date:6/2/2008

GSK exercises option for AM803, a FLAP inhibitor which recently completed

phase I studies

SAN DIEGO, June 2 /PRNewswire/ -- Amira Pharmaceuticals today announced that under the terms of a worldwide exclusive agreement entered into in Feb 2008, GlaxoSmithKline (GSK) will exercise its right to a second FLAP compound, AM803. Under the original agreement, GSK has rights to develop, manufacture and commercialize FLAP (5-Lipoxygenase Activating Protein) inhibitors for the treatment of respiratory and cardiovascular disease. The decision to develop AM803 follows the successful completion of a phase I study by Amira, which demonstrated its potential as a once-daily FLAP inhibitor.

"Exercise of this option by GSK caps a productive first few months during which Amira has hit a number of near term milestones. Hitting these milestones early has not only further strengthened our relations with GSK, but has resulted in meaningful economic benefit to Amira," said Hari Kumar, Chief Business Officer, Amira. "The project has started extremely well and we are very pleased at the commitment of GSK and the progression of development."

About FLAP Inhibitors

FLAP (5-Lipoxygenase Activating Protein) is a key component early in the leukotriene pathway, a complex signaling process that exerts control over biological processes, such as inflammation and immunity. Excessive production of leukotrienes exacerbates inflammatory diseases, such as asthma; the FLAP gene has also been linked to a significant increase in the risk of myocardial infarction and stroke. AM103 and AM803 bind to FLAP, inhibiting the synthesis of leukotrienes that cause inflammation.

About Amira

Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of compounds to treat inflammatory disease linked to the eicosanoid pathway.

The company co
'/>"/>

SOURCE Amira Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Dr. Dennis Fenton and Dr. Steve Kaldor Join Amira Board of Directors
2. Amira Pharmaceuticals and GlaxoSmithKline Enter Global Agreement for FLAP Inhibitor Program
3. Amira Pharmaceuticals Appoints First Vice President of Development
4. Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial Results for Lead Product Candidate AM103 and Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease
5. Vion Pharmaceuticals Announces Presentation of Data from Phase III Trial of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting
6. Lotus Pharmaceuticals, Inc. Reaffirms its Confidence in Meeting its Make Good Target for Fiscal Year 2008
7. Anthony Clarke, PhD Joins Alexza Pharmaceuticals as Vice President, International Development Operations
8. Alseres Pharmaceuticals, Inc. Announces 2008 Annual Stockholders Meeting
9. Lotus Pharmaceuticals, Inc. Announces Conference Call to Discuss First Quarter 2008 Results
10. Watson to Present at the UBS Global Specialty and Generic Pharmaceuticals Conference
11. Vanda Pharmaceuticals to Present at the FBR Capital Markets 12th Annual Spring Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 20, 2014 Principle Business Enterprises, a ... in manufacturing top-of-the-line absorbent products. The company has ... most popular brand, Tranquility® Premium Protection absorbent products. ... website, gave its packaging a new look, and is ... message to the public. , The new website, developed ...
(Date:10/20/2014)... Based on a proprietary chromatid-specific ... assays capable of determining DNA sequence, location and ... three dimensions of high-resolution data, dGH assays are ... range of disease-causing genetic rearrangements, including chromosomal inversions ... tools, including today’s advanced sequencing technologies. , According ...
(Date:10/20/2014)... New York, NY (PRWEB) October 20, 2014 ... to be introduced in the U.S., has a lot to ... time when our country recognizes the achievements and contributions of ... marks the anniversary for Punzoné, and today it shares its ... and take a trip to Italy - even if it ...
(Date:10/19/2014)... 20, 2014 Recently, BambooIndustry.com, one of ... its new range of bamboo deckings . Moreover, ... natural items; they are now available at deeply discounted ... it is hard to overstate the significance of online ... to online services. The company’s workers are striving to ...
(Date:10/19/2014)... Recently, Fancyflyingfox.com, an innovative company that provides many kinds ... designs of 2014 mother of the bride dresses ... offered with big discounts, up to 70% off. All ... enjoy this special offer. , Owing to the ... one of the leading brands in the global market. ...
Breaking Medicine News(10 mins):Health News:Tranquility® Premium Protection Incontinence Products Releases New Logo and Website 2Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 2Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 3Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 4Health News:High Quality Bamboo Deckings, New Items Unveiled By BambooIndustry.com 2Health News:Fancyflyingfox.com Updates Its Website With New Mother Of The Bride Dresses For 2014 2
... Omnicell, Inc.,(Nasdaq: OMCL ), a leading provider ... its Board of Directors has approved the,repurchase of an ... Stock over,the next 12 months. The Company,s Board of ... review of the Company,s financial position and,investment alternatives. The ...
... Fla. -- With a four-year, $707,000 grant from the American ... the Florida State University College of Medicine, hopes to learn ... on the runaway cell division process that occurs in many ... an enzyme known as Cdc14 in deactivating the cell division ...
... Genomatix Software GmbH, a Systems Biology company focussed on ... has begun showcasing its abilities in the analysis of ... Allan P. Boyle et al published in the January ... and Characterization of Open Chromatin across the Genome where ...
... 32% to $14.2 Million ... Quarterly Record, MINNEAPOLIS, Feb. 25 ATS Medical, Inc.,(Nasdaq: ... and services, today reported financial results for the,fourth quarter and ... $14.2 million, up 32.4% from $10.7 million reported in the,fourth ...
... never filled after hospital discharge, study found , , MONDAY, Feb. ... survive heart attacks don,t take the drugs prescribed for them ... That failure to adhere to medication increases the patient,s risk ... "About one in five of all prescriptions weren,t filled after ...
... Corp. and Capital Growth Planning Inc., form "MaxLife-CGP",Partners LLC., a ... approximately $25M to $100M dollars in face value, ... 1 ... throughout 2008., CALIFORNIA, Feb. 25 /PRNewswire-FirstCall/ - MaxLife Fund ...
Cached Medicine News:Health News:Omnicell Announces Common Stock Repurchase Program; Reaffirms Earnings Forecast 2Health News:Omnicell Announces Common Stock Repurchase Program; Reaffirms Earnings Forecast 3Health News:FSU College of Medicine researcher seeks to uncover new cancer therapies 2Health News:Genomatix integrates genome-wide open chromatin from next generation sequencing 2Health News:ATS Medical Announces Record Quarterly and Full Year Revenue 2Health News:ATS Medical Announces Record Quarterly and Full Year Revenue 3Health News:ATS Medical Announces Record Quarterly and Full Year Revenue 4Health News:ATS Medical Announces Record Quarterly and Full Year Revenue 5Health News:ATS Medical Announces Record Quarterly and Full Year Revenue 6Health News:ATS Medical Announces Record Quarterly and Full Year Revenue 7Health News:ATS Medical Announces Record Quarterly and Full Year Revenue 8Health News:ATS Medical Announces Record Quarterly and Full Year Revenue 9Health News:ATS Medical Announces Record Quarterly and Full Year Revenue 10Health News:Many Patients Fail to Take Drugs After Heart Attack 2Health News:Many Patients Fail to Take Drugs After Heart Attack 3Health News:MaxLife Fund Corp. and Capital Growth Planning Inc., sign a joint venture agreement 2Health News:MaxLife Fund Corp. and Capital Growth Planning Inc., sign a joint venture agreement 3
(Date:10/17/2014)... 17, 2014  Hanger, Inc. (NYSE: HGR ... results of operations for the quarter ended September 30, ... closes.  A conference call to discuss these results is ... November 7, 2014. Those wishing to participate should call ... 14, 2014 by dialing 1-855-859-2056 and referencing Conference ID ...
(Date:10/17/2014)... October 17, 2014 ... has announced the addition of the  "China ... their offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... in China impacted ... in consumption concept, dietary habit, way of ...
(Date:10/17/2014)... DUBLIN , October 17, 2014 ... Research and Markets ( http://www.researchandmarkets.com/research/rxznjk/micro_market ) has ... Market Monitor : North American Automated ... their offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ,The ... forecast, 2008-2018 analyzes the market of ...
Breaking Medicine Technology:China Interventional Cardiovascular Device Industry Report 2014-2017 2China Interventional Cardiovascular Device Industry Report 2014-2017 3Micro Market Monitor : North American Automated External Defibrillators (AED) Market 2
... Improvement With Every-Four-Week Subcutaneous SIMPONI Despite Previous Medication ... June 9 A new analysis demonstrated that ... severely active rheumatoid arthritis (RA) who had prior ... received subcutaneous injections of SIMPONI(TM) (golimumab) once every ...
... in June Issue of Circulation , , SILVER ... Corporation (Nasdaq: UTHR ) and Eli Lilly ... the results of a pivotal 16-week study showing that ... improved exercise capacity and improved time to clinical worsening ...
Cached Medicine Technology:New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 2New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 3New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 4New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 5New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 6New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 7New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 8New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 9New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 10Study Results Present Efficacy and Safety Findings from the PHIRST-1 Study of Patients with Pulmonary Arterial Hypertension Taking Tadalafil Tablets Once Daily 2Study Results Present Efficacy and Safety Findings from the PHIRST-1 Study of Patients with Pulmonary Arterial Hypertension Taking Tadalafil Tablets Once Daily 3Study Results Present Efficacy and Safety Findings from the PHIRST-1 Study of Patients with Pulmonary Arterial Hypertension Taking Tadalafil Tablets Once Daily 4Study Results Present Efficacy and Safety Findings from the PHIRST-1 Study of Patients with Pulmonary Arterial Hypertension Taking Tadalafil Tablets Once Daily 5Study Results Present Efficacy and Safety Findings from the PHIRST-1 Study of Patients with Pulmonary Arterial Hypertension Taking Tadalafil Tablets Once Daily 6
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
For use with catalog #0540....
Lupus Anticoagulant-Sensitive APTT Reagent.Cephalin with particulate activator (silica), freeze-dried....
Antigenic Total Protein S, ELISA Method...
Medicine Products: